MedTrace Logo

Study of Capsaicin Patch for the Management of Peripheral Neuropathic Pain

NCT02228928 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-05-01

No results posted yet for this study

Summary

The efficacy and safety of the low concentration \[0.65% (50 µg/cm2) and 1.25% (100 µg/cm2)\] capsaicin patches and compared them to conventional 0.075% capsaicin cream and placebo patch in patients suffering from peripheral neuropathy

Conditions

  • Peripheral Nerve Injury
  • Postherpetic Neuralgia

Interventions

DRUG

CAPNP, 50 ug/cm2 capsaicin patch

DRUG

CAPNP, 100 ug/cm2 capsaicin patch

DRUG

0.075% capsaicin cream

OTHER

Placebo patch

Sponsors & Collaborators

  • Samyang Biopharmaceuticals Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02228928 on ClinicalTrials.gov